FDA Brief

Warning letters Drugs

FDA warning letter to

Ivim Services LLC dba Ivim

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.

What happened

FDA reviewed the website https://www.ivimhealth.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The pictured labels show "Ivim," which suggests Ivim made the drugs when it did not. FDA calls those statements false or misleading, which makes the products misbranded (labeled or promoted in a way that is false or misleading).

What FDA found

  1. The website labels name "Ivim" on compounded semaglutide and tirzepatide, implying Ivim is the maker of drugs it does not make, so the labeling is false or misleading.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. Advertising or promotion of a compounded drug is illegal if it is false or misleading in any way, which FDA says this was.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. Shipping misbranded drugs, or arranging to ship them, between states is a prohibited act.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. Receiving misbranded drugs and delivering or offering to deliver them is also a prohibited act.

    FDCA section 301(c) [21 U.S.C. § 331(c)]
  5. A name on a drug label with no qualifying words means that named person is the only manufacturer, so using it otherwise is misleading.

    21 CFR § 201.1(h)(2)
  6. Compounded drugs must meet the conditions of sections 503A or 503B to be excused from the new drug approval requirements.

    FDCA sections 503A and 503B [21 U.S.C. §§ 353a, 353b]

What FDA wants

Within 15 working days, Ivim must send a written response to FDA's Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent them from recurring. FDA specifically asks the company to identify who makes the compounded products, supply sample labeling, and address or correct the other website claims FDA may find misleading.

Who should pay attention

  • telehealth companies marketing compounded semaglutide or tirzepatide
  • compounding pharmacies whose products are sold under someone else's name online
  • marketing and brand teams that approve drug labeling and website claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low